Skip to content

Study · Randomized controlled trial · n = 24 · 1990

4 results

A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection.

Roy JB, Petrone RL, Said SI

The Journal of urology1 Feb 1990Cited by 34 (Europe PMC)

PMID2405186 (opens in a new tab)DOI10.1016/s0022-5347(17)39939-1 (opens in a new tab)PepBankPUB-02405186
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In 24 men with erectile dysfunction, intracavernous VIP increased penile length, and the increase was dose-related.

    In plain wordsIn 24 men with erectile dysfunction, VIP injected into the penis increased penile length, more at the higher dose.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePenile length increase
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    200 or 400 pmol · intracavernous injection · 3 consecutive weekly visitsAs given in this study (human).

    Source sentences

    Summary
    An increase in penile length was associated significantly with treatment (F equals 5.10, p equals 0.01), dose-related, and independent of the time and sequence of treatment.
    2 context sentences
    Summary · context
    A double-blind, placebo-controlled clinical trial of the intracavernous injection of vasoactive intestinal peptide was conducted and studied in 24 men with erectile dysfunction of diabetic, neurogenic and psychogenic etiology.
    Summary · context
    The patients were randomized into 6 groups of 4 subjects each and received either placebo, or 200 or 400 pmol. vasoactive intestinal peptide at each of 3 consecutive weekly visits.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In 24 men with erectile dysfunction, intracavernous VIP increased penile diameter, and the increase was dose-related.

    In plain wordsIn 24 men with erectile dysfunction, VIP injected into the penis increased penile diameter, more at the higher dose.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePenile diameter increase
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    200 or 400 pmol · intracavernous injection · 3 consecutive weekly visitsAs given in this study (human).

    Source sentences

    Summary
    An increase in penile diameter was associated significantly with treatment (F equals 8.14, p equals 0.001) and time (F equals 8.14, p equals 0.001), dose-related and independent of the sequence of treatment.
    2 context sentences
    Summary · context
    A double-blind, placebo-controlled clinical trial of the intracavernous injection of vasoactive intestinal peptide was conducted and studied in 24 men with erectile dysfunction of diabetic, neurogenic and psychogenic etiology.
    Summary · context
    The patients were randomized into 6 groups of 4 subjects each and received either placebo, or 200 or 400 pmol. vasoactive intestinal peptide at each of 3 consecutive weekly visits.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In 24 men with erectile dysfunction, penile rigidity was only nearly significantly associated with VIP treatment (p equals 0.056).

    In plain wordsIn 24 men with erectile dysfunction, VIP did not clearly increase penile rigidity; the link with treatment was close to, but not at, significance.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePenile rigidity
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    200 or 400 pmol · intracavernous injection · 3 consecutive weekly visitsAs given in this study (human).

    Source sentences

    Summary
    Penile rigidity was associated significantly with time (F equals 5.44, p equals 0.008), associated nearly significantly with treatment (F equals 3.11, p equals 0.056) and independent of sequence of treatment.
    2 context sentences
    Summary · context
    A double-blind, placebo-controlled clinical trial of the intracavernous injection of vasoactive intestinal peptide was conducted and studied in 24 men with erectile dysfunction of diabetic, neurogenic and psychogenic etiology.
    Summary · context
    The patients were randomized into 6 groups of 4 subjects each and received either placebo, or 200 or 400 pmol. vasoactive intestinal peptide at each of 3 consecutive weekly visits.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In 24 men with erectile dysfunction, no patient reached penile rigidity adequate for intromission after VIP.

    In plain wordsIn 24 men with erectile dysfunction, no man reached an erection firm enough for intercourse after VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeRigidity adequate for intromission
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    200 or 400 pmol · intracavernous injection · 3 consecutive weekly visitsAs given in this study (human).

    Source sentences

    Summary
    Despite some measurable treatment-related increase none of the patients achieved penile rigidity adequate for intromission.
    2 context sentences
    Summary · context
    A double-blind, placebo-controlled clinical trial of the intracavernous injection of vasoactive intestinal peptide was conducted and studied in 24 men with erectile dysfunction of diabetic, neurogenic and psychogenic etiology.
    Summary · context
    The patients were randomized into 6 groups of 4 subjects each and received either placebo, or 200 or 400 pmol. vasoactive intestinal peptide at each of 3 consecutive weekly visits.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.